Streetbeat News

ALPMY

Astellas Pharma Inc.

https://www.astellas.com/jp/

CEO

Kenji Yasukawa

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Open

10.08

Mkt cap

18B

Volume

5.6K

High

10.10

P/E Ratio

50.30

52-wk high

13.14

Low

10.06

Div yield

0.05

52-wk low

9.15

Astellas has announced a collaboration with YASKAWA to develop an innovative cell therapy ecosystem by integrating pharmaceutical and robotics technologies.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 4:59 am

Astellas and Poseida Therapeutics have entered into a research collaboration and license agreement to develop novel allogeneic cell therapies for oncology, focusing on solid tumors using Poseida's proprietary allogeneic CAR-T platform.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 7:29 am

Astellas' XTANDI (Enzalutamide) has received approval from the European Commission for use in a new treatment setting for high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer in the EU. This makes XTANDI the first novel hormone therapy available for this condition in the EU. The approval is based on the positive results from the Phase 3 EMBARK study, which demonstrated that XTANDI, alone or in combination with leuprolide, significantly reduced the risk of metastasis or death.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 6:23 am

Astellas has submitted a supplemental new drug application in Japan for the combination of PADCEV™ (enfortumab vedotin) and KEYTRUDA® (pembrolizumab) as a first-line treatment for advanced bladder cancer. The pivotal trial showed that this combination significantly improved overall and progression-free survival compared to the current standard platinum-containing chemotherapy. If approved, it would be the first non-chemotherapy combination treatment for this condition in Japan.

Portfolio Pulse from Benzinga Newsdesk

January 31, 2024 | 6:34 am

The Global Data report indicates a decrease in pharma sector M&A deals in Q3 2023 compared to Q2 2023, with a 28% drop in deal value and a 9% drop in deal volume. However, PricewaterhouseCoopers forecasts a positive outlook for 2024, expecting a return to pre-pandemic levels of M&A activity. Notable deals in 2023 include acquisitions by Pfizer, Bristol Myers Squibb, Merck, AbbVie, Biogen, and Astellas Pharma.

Portfolio Pulse from Vandana Singh

December 29, 2023 | 12:04 pm

Elpiscience and Astellas Pharma have entered into a research collaboration and license agreement to develop a novel bispecific macrophage engager, which could have implications for cancer treatment. The financial terms and specific details of the collaboration were not disclosed in the article.

Portfolio Pulse from Benzinga Newsdesk

December 28, 2023 | 6:58 am

The European Medicines Agency has recommended Astellas Pharma Inc.'s drug, Arpraziquantel, for the treatment of schistosomiasis in preschool-aged children. This recommendation could lead to increased use of the drug in this age group across Europe.

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 6:19 am

The FDA has approved Merck's KEYTRUDA in combination with Padcev for first-line treatment of locally advanced or metastatic urothelial cancer. The approval, based on the Phase 3 KEYNOTE-A39 trial, showed significant improvement in overall survival and progression-free survival compared to platinum-based chemotherapy. The trial also demonstrated a higher objective response rate with the KEYTRUDA plus Padcev combination. This approval was granted ahead of the PDUFA goal date and was part of the FDA's Real-Time Oncology Review program.

Portfolio Pulse from Happy Mohamed

December 16, 2023 | 11:38 pm

The European Commission has approved Astellas' VEOZA™ for the treatment of vasomotor symptoms associated with menopause. This approval could potentially increase Astellas' market presence in Europe and contribute to future revenue growth.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 7:17 am

Astellas Pharma and Pfizer have received FDA approval for a supplemental marketing application for Xtandi (enzalutamide) to treat nonmetastatic castration-sensitive prostate cancer with a high risk of metastasis after biochemical recurrence.

Portfolio Pulse from Benzinga Newsdesk

November 17, 2023 | 8:52 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.